Press Releases
Alzheon to Make Presentations at Upcoming Industry and Investor Conferences
Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences ConferenceFRAMINGHAM, Mass., May 22, 2017 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused [...]
Alzheon Launches Roadshow for Initial Public Offering
FRAMINGHAM, Mass., April 2, 2018 – Alzheon, Inc. (“Alzheon”) announced today that it has launched the roadshow for the initial public offering of its common stock. Alzheon [...]
Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease
Therapeutic Inhibition of Toxic Beta Amyloid Oligomers Can Intervene Early in Amyloid Aggregation Cascade Two Additional Posters at CTAD Support Advancement of ALZ-801 to Phase 3 Study [...]
FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease
Company’s Phase 3 Clinical Program Pioneers a Precision Medicine Approach in Alzheimer’s Disease FRAMINGHAM, Mass. – October 24, 2017 – Alzheon, Inc., a clinical stage biopharmaceutical company [...]
Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease
Results Support Pivotal Phase 3 Development of ALZ-801 in Genetically-Defined APOE4/4 Patients and Further Expansion to Additional Alzheimer’s Populations FRAMINGHAM, Mass., October 24, 2017 – Alzheon, [...]
Alzheon to Make Presentations on ALZ-801 and its Anti-Oligomer Mechanism at the 10th Clinical Trials on Alzheimer’s Disease Congress
Clinical Data and Research Support Advancement of ALZ-801 to Phase 3 Study as Oral Precision Medicine to Treat Alzheimer’s Disease FRAMINGHAM, Mass., October 12, 2017 – [...]